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Running head: Serum vitamin D, variants in vitamin D genes and age-related macular 
degeneration  
 Abstract  
Objective: To study associations between early and late age-related macular degeneration 
(AMD) and the neovascular type of late AMD (nvAMD) with serum 25-hydroxy vitamin D 
(25(OH)D) and genetic variants in vitamin D pathway genes. 
Design: Population-based cross-sectional study in a random sample aged 65 and over from seven 
European countries.  
Participants: Of 4753 participants, 4496 (2028 men and 2468 women) ,mean age 73, provided a 
usable blood sample; 2137 had no signs of AMD, 2209 had early AMD, 150 had late AMD of 
which 104 nvAMD. 
Methods: Participants were interviewed for smoking and alcohol use, brief medical history, 
sunlight exposure and a dietary questionnaire, underwent color fundus photography and provided 
a blood sample. Fundus images were graded using the modified International Classification 
System for Age Related Maculopathy. 25(OH)D was measured by liquid chromatography-
tandem mass spectrometry and categorized as deficient (< 30 nmol/L), insufficient (30–50 
nmol/L), adequate (≥50 nmol/L). Genotyping was performed on a sub-sample of 1284 AMD 
cases and controls for 93 SNPs from seven genes. Associations were investigated by linear or 
logistic regression adjusted for potential confounders.  
Main Outcome Measures: Adjusted odds ratio (AOR) for three outcomes (early AMD, late 
AMD, nvAMD).  
Results: No linear association was found with 25(OH)D and early or late AMD or nvAMD. 
There was no association between insufficient or deficient status with early or late AMD. 
Deficient status was associated with nvAMD (AOR = 1.27, 95% Confidence Interval 1.1-1.45, p 
<0.0001).  Significant (p<0.05) associations with 25(OH)D were found for SNPs in genes GC, 
 VDR ,CYP2R1, CYP27B1.  Using a initial threshold of p<0.05, two SNPs (VDR) were associated 
with early AMD, four SNPs (RXRA) and one (VDR) with nvAMD and one (RXRA), two (VDR) 
and one (CYP2R1) with late AMD.  After Bonferroni correction, no SNPS were associated with 
early, late or nvAMD. 
Conclusions: 25(OH)D deficient status was associated with nvAMD but  the adjusted OR was 
small and we cannot exclude residual confounding.  The hypothesis of a causal association of 
vitamin D with AMD is not supported by clear evidence for an association of vitamin D pathway 
SNPs with early, late or nvAMD.  
 Vitamin D is produced in the skin following exposure to ultraviolet B (UVB) radiation as 
vitamin D3 (cholecaliferol), and to a lesser extent, obtained from the diet (principally oily fish).
1
  
The other natural source of vitamin D, Vitamin D2 (ergocalciferol) is found in a few foods and 
provides a much smaller proportion of dietary vitamin D.  Other sources of vitamin D include 
supplements or, in some countries, fortified foods.  In the body the biologically active metabolite 
of vitamin D3, 1,25-dihydroxyvitamin D (1,25(OH)2D3) is distributed to the tissues and plays an 
important role in a number of biological functions, including calcium homeostasis, immune 
response and insulin metabolism.
2
  Serum 25-hydroxyvitamin D (25(OH)D) measures the total 
circulating vitamin D (D2 and D3) and is used as a measure of vitamin D status.  In countries of 
the European Union where supplement use is relatively low and foods are not fortified, 25(OH)D 
deficiency has been found in 13% of the overall population.
3
  In addition to environmental 
factors, genetic variants influence 25(OH)D concentrations and single nucleotide polymorphisms 
(SNPs) in a number of genes related to uptake and metabolism have been identified.
4, 5
 
Recommendations for desirable levels of 25(OH)D of  at least 50 nmol/L
6
 go beyond avoiding 
deficiency to maximizing bone health.  Vitamin D has also been postulated to influence disease 
risk across a wide range of other conditions suggesting the potential benefit from increasing 
vitamin D by diet or supplementation.  However, a clear picture has not emerged.  A large body 
of evidence summarized in recent systematic reviews and meta analyses, based on nearly 300 
observational studies and 200 randomized controlled trials (RCTs), showed reduced risks of all-
cause mortality, cardiovascular disease (CVD) incidence and mortality in the observational 
studies but not in the RCTs except for all-cause mortality.
7, 8
  
 
 Age related macular degeneration (AMD) is characterized by progressive degenerative changes 
in the retina. Late stage AMD consists of neovascular AMD (nvAMD) and geographic atrophy 
(GA).  Hypotheses for an association of vitamin D with AMD are based on the anti-
inflammatory role of vitamin D, identification of vitamin D receptors in retinal tissues,
9, 10
 and 
the major role of inflammation and of complement-related genes and complement activation in 
the development of AMD.
11
  CVD and risk factors for CVD such as smoking and diabetes are 
additionally risk factors for nvAMD.
12
  There are inconsistent findings from studies investigating 
the association of 25(OH)D with AMD.
9, 13-17
 Most studies lacked power to investigate late AMD 
13-16
 or reported an association with early
16
 or late
17
 AMD only in sub-groups (by gender or age).  
Early AMD was associated with lower concentrations of 25(OH)D in some
13,15
 but not all 
studies.
14
  Other studies investigating vitamin D and late AMD were based on diagnoses from 
medical records 
18-20
 or from a case series.
21
  Two studies reported inconclusive findings for 
SNPs in genes influencing 25(OH)D concentrations with early
15
 or late AMD
9
.  In the absence of 
clear evidence on this important question, we investigated associations between 25(OH)D and 
SNPs in seven vitamin D related genes with AMD in the European Eye Study (EUREYE).   
 
Methods 
Participants were recruited by random sampling of the population aged 65 years and older in 
seven centers across Europe: Bergen (Norway), Tallinn (Estonia), Belfast (UK), Paris (France), 
Verona (Italy), Thessaloniki (Greece) and Alicante, (Spain). Participants were interviewed by 
trained fieldworkers, underwent fundus photography, and provided blood samples.  Information 
collected at interview included education, smoking and alcohol use, a brief medical history, a 
semi-quantitative food frequency questionnaire, and a detailed questionnaire to estimate 
 ultraviolet radiation exposure (UVR) (see below).  Written informed consent was obtained from 
all study participants.  Institutional Review Board (IRB)/Ethics Committee approval was 
obtained for each center. The study adhered to the tenets of the Declaration of Helsinki.  
Fundus photography and grading 
After pupillary dilation with tropicamide 0.5% and phenylephrine 5%, two 35° non-simultaneous 
stereoscopic digitized color fundus images centered on the fovea were obtained of each eye.  The 
fundus images were sent to a single reading center (Erasmus University Rotterdam) and graded 
using the International Classification System for Age-Related Maculopathy
22
 and then 
categorized into five mutually exclusive grades.  Grade 0 was defined as a macula free of drusen 
or pigmentary irregularities or with hard drusen (< 63 µm) only. Early AMD was subdivided in 
grade 1, defined as soft distinct drusen (≥ 63 µm) or pigmentary abnormalities, grade 2 as soft 
indistinct drusen (≥ 125 µm) or reticular drusen only or soft distinct drusen (≥ 63 µm) with 
pigmentary abnormalities, and grade 3 as soft indistinct drusen (≥ 125 µm) or reticular drusen 
with pigmentary abnormalities.  Grade 4 was defined as presence of either nvAMD (presence of 
any of the following: serous or hemorrhagic retinal or retinal pigment epithelial detachment, 
subretinal neovascular membrane, periretinal fibrous scar) or GA (well-demarcated area of 
retinal pigment atrophy with visible choroidal vessels).   
Measurement of UV exposure 
Full details of UV measurement have been published previously
23
.  We used a detailed 
questionnaire to ascertain lifetime residence and time spent outdoors (from age 14), for work 
(including homecare), leisure and retirement up to current age.  Information from the 
questionnaire, residence calendar and geographical co-ordinates for residence were sent to the 
University of East Anglia to estimate years of exposure for different wavelengths of UVR (UVA, 
 UVB and blue light) using published sources that take into account time of day, month, and 
latitudinal variations.  Personal adult lifetime UV exposure were estimated for each of the three 
wavelengths of light and summed for a mean annual lifetime dose for all day exposures and for 
exposures in the middle of the day.  
Blood analyses 
Non-fasting venous blood samples were separated within 4 hours of collection and serum was 
stored at -20
○
C for up to 4 weeks before frozen samples were transferred to a single laboratory 
(Queens University Belfast) for storage at -80
○
C.   Antioxidant and cholesterol analyses were 
carried out within 3 months of storage. Plasma lutein, zeaxanthin, beta cryptoxanthin, alpha and 
beta-carotene, alpha and gamma tocopherol, lycopene and retinol were measured by reverse 
phase high pressure liquid chromatography.  Plasma vitamin C was measured using an enzyme-
based assay in plasma stabilized with metaphosphoric acid.  All assays were standardized against 
appropriate National Institute of Standards and Technology (NIST) standard reference materials.  
Serum cholesterol was measured using an enzymatic assay (Randox, Crumlin, UK) on a Cobas 
FARA centrifugal analyzer (Roche Diagnostics, UK). Serum 25-hydroxy vitamin D2 and D3 
(25(OH)D2 and 25(OH)D3) were measured by liquid chromatography-tandem mass spectrometry 
(LC-MS/MS) 8 to 10 years after initial collection.  
SNP selection and Genotyping 
For reason of costs, genotyping was undertaken in a sub-sample of the main study.  A random 
sample of controls (AMD grade 0) was frequency matched on age (within a year), sex and center 
with all cases of (i) late AMD, and (ii) all cases with early AMD grades 2 and 3.  Cases with 
AMD grade 1 were not investigated.  Ninety-three common SNPs located across 7 genes 
involved in the vitamin D metabolic pathway (GC (10), RXRA (14), CYP2R1 (7), DHCR7 (5), 
 VDR (29), CYP27B1 (7), CYP24A1 (21) were selected from Phase III, release 2 HapMap 
(http://www.hapmap.org) CEPH data (Utah residents with ancestry in northern and western 
Europe; CEU) using Haploview (http://www.broadinstitute.org/haploview) to determine linkage 
disequilibrium.  Tag SNPs were selected using multimarker tagging where r
2
>0.8 for all 
downloaded SNPs with a minor allele frequency (MAF) ≥5%, genotype call rate ≥95%, and no 
significant deviation from Hardy Weinberg equilibrium (HWE). Genotyping was performed by 
KBiosciences (Hoddesdon, United Kingdom). Quality filters for exclusion of SNPs included call 
rates below 95% and deviation from HWE (P<0.001).  DNA samples were excluded if missing 
genotypes exceeded 10%.  Other quality control measures included duplicates on plates, random 
sample allocation to plates, independent scoring of problematic genotypes by two individuals 
and re-sequencing of selected DNAs to validate genotypes.  KBiosciences quality control also 
included validation of all SNP assays on a panel of 44 random Caucasian-derived samples plus 4 
non-template (negative) controls.  
Data processing and statistical analysis  
Statistical analysis was carried out using Stata software version 13 (Stata Corp., College Station, 
TX) and PLINK (version 1.07) under an additive genotypic model.
24
  We investigated total 
25(OH)D i.e. 25(OH)D2 plus 25(OH)D3 as (i) a continuous variable and (ii) categorized by 
clinical status based on expert guidelines as: deficient (< 30 nmol/L), insufficient (30–50 
nmol/L), and adequate (≥50 nmol/L).6  We excluded extreme values of ≥150 nmol/L (n=17). 
25(OH)D was normalized using a square root transformation due to a long right hand tail (110 
participants had values ≥100 and <150 nmol/L). Dietary vitamin D was estimated using food 
composition tables
25
 and adjusted for total energy intake.
26
  All day UVB exposures were square 
root transformed and lutein concentrations log transformed. We ran preliminary regression 
 analyses to identify factors associated with 25(OH)D as possible confounders of any association 
with AMD and carried out a similar analysis for vitamin D status.  We used univariable and 
confounder-adjusted logistic regression to investigate associations between 25(OH)D or vitamin 
D status and early grades of AMD and nvAMD.  We also present results for all late AMD 
(nvAMD and GA combined) as numbers with GA were too small (n=46) to permit meaningful 
separate analyses.  Analyses took account of the study design by including study centre in 
models and by use of robust errors in Stata.
27
 We report associations of individual SNPs with 
early, late and nvAMD at a nominal significance of p<0.05.  Since our a priori hypothesis of an 
association between SNPs in vitamin D-related genes and AMD was based on previously 
demonstrated associations of vitamin D genes with 25(OH)D,
4
 
5
 we applied a Bonferroni 
correction based on  the number of SNPs within each gene in the AMD analyses in preference to 
a GWAS type correction for all 92 snps.  We also investigated whether any association of 
25(OH)D status and nvAMD or early AMD was modified by the main AMD genetic risk loci, 
rs1061170 in CFH and rs10490924 in ARMS2,as has been reported previously.
15
 
 
Results 
Serum 25(OH)D 
Of 4753 participants at the clinical examination, 4496 provided a usable blood sample for the 
vitamin D assays.  Of these 2137 had no signs of AMD, 2209 had early AMD; 1635 (grade 1), 
460 (grade 2), 114 (grade 3), 46 (GA) and 104 nvAMD.  The mean (standard deviation, SD) of 
25(OH)D concentrations  was 49 (23) nmol/L.  The highest mean seasonally-adjusted 
concentration was observed in the Bergen center (63 (20) nmol/L) compared to all other centers 
with adjusted differences ranging from 20 nmol/L lower concentrations in Paris, approximately 
 15 nmol/L lower in Tallinn, Belfast, Verona and Thessaloniki, to 9 nmol/L in Alicante (all 
comparisons p <0.0001).  Vitamin D deficiency was found in 21% (n=944) and 32.8% (1475) 
were classified as insufficient.  Only 13.4% (604) had concentrations of 75 nmol/L or greater.  A 
large number of variables were independently associated with 25(OH)D.  In multivariable 
analyses adjusted for center and season, levels were lower with increasing age, in women, in 
current smokers, participants with diabetes, and higher in those taking fish oil supplements, and 
drinking alcohol at least weekly.  25(OH)D was associated with higher UVB exposure, dietary 
vitamin D intake, serum cholesterol, and plasma concentrations of ascorbate, lutein (or 
zeaxanthin), and retinol (all associations, p<0.05 or less).  There was no association with 
education.  Lutein and zeaxanthin were highly correlated (r=0.85) and therefore associations with 
25(OH)D were almost identical.  The characteristics of people categorized by 25(OH)D status 
are shown in Table 1 (univariable analyses).  Proportionately fewer people classified as 
insufficient or deficient took fish oil supplements or consumed oily fish at least weekly, were 
less likely to be in the highest quartile of dietary vitamin D intake, or dietary docosahexaenoic 
acid intake, and were more likely to be older or obese compared to those with sufficient levels.  
Associations with AMD 
Covariate-adjusted models showed no association of 25(OH)D with any grade of early AMD or 
late or  nvAMD  (Table 2).  25(OH)D status was not associated with any grade of early or late 
AMD (Table 2).  For nvAMD, deficient status was associated with a covariate adjusted OR of 
1.27, 95% confidence interval (1.11-1.45) p<0.0001. Although numbers with GA were small 
there was no indication of increased odds for deficiency status (OR=0.82, 0.36- 1.89). We found 
no significant interactions with rs1061170 or rs10490924 with 25(OH)D status and nvAMD 
(p=0.32 and 0.30 respectively) or early AMD (p=0.28 and 0.11).  
 Genetic associations 
Genotype data were available for 93 SNPs from 1284 participants selected for genetic analysis.  
One SNP in GC was excluded for failing to meet the quality filters of call rates below 95% or 
deviation from HWE (P<0.001). The average call rate for the remaining SNPs was 99.3%. No 
participants were excluded due to insufficient genotype data. No duplicate inconsistencies were 
observed.  Results for all 92 SNPs and their age, sex and center adjusted association with 
25(OH)D (additionally adjusted for season),  early,late, nvAMD are provided in  Tables 3-6 
(available at http://www.aaojournal.org).  Nominal significant results are summarized in 
Table7.  Our results confirmed that SNPs in GC (3), RXRA (1), CYP2R1 (2), VDR (1) and 
CYP27B1 (1) were associated with 25(OH)D. Two SNPs both in VDR (rs11574026, rs4516035) 
were significantly associated with early AMD. Five SNPs were significantly associated with 
nvAMD: four in RXRA (rs11185644, rs12339187, rs10881582, rs3118536,) and one in VDR 
(rs11574077). Analysis of late AMD identified four significantly associated SNPs following the 
inclusion of participants with GA. These were rs3118536 in RXRA, rs10875693 and rs11574077 
in VDR, and rs11023371 in CYP2R1. After applying Bonferroni corrections of p=0.004 for 14 
RXRA SNPs and p=0.002 for 29 VDR SNPS, no SNPs were associated with early AMD, nvAMD 
or late AMD. 
 
Discussion 
We found no linear association between 25(OH)D and early or nvAMD.  25(OH)D deficiency 
status was associated with nvAMD, adjusted OR of 1.27.  Insufficient 25(OH)D status was not 
associated with nvAMD.  
 Few studies have investigated associations between 25(OH)D and late AMD with inconsistent 
results.  Several studies have used historical medical records and linked information on vitamin 
D to a diagnosis of late AMD.   No  association was found with nvAMD in a  Medicare study of 
7000 people with a diagnosis of Vitamin D deficiency and matched controls followed for 3 
years.
18
  Retrospective medical records identification of 146 nvAMD patients tested for vitamin 
D compared with 100 age, sex and race matched controls with pseudophakia, reported an 
adjusted OR of 0.37 (CI 0.19- 0.72) between the highest and lowest quintile of 25(OH)D.
20
  A 
health records study in Israel of 9267 participants with a routine 25(OH)D measurement 
identified 1045 individuals with a diagnosis of AMD (grade and severity not available) and 
found no differences in 25(OH)D compared to non-AMD participants; results were not adjusted 
for age although AMD cases were older than non-AMD.
19
  Using  records of  a mobile geriatric 
clinic of 26 late AMD cases and 34  with no AMD signs,  25(OH)D deficiency was associated 
with  a 3 fold OR, 95% CI, 1-9,  results were adjusted only for age, sex and season of blood 
collection.
28
 
An inverse association was found between early AMD and 25(OH)D in the US National Health 
and Nutrition Examination survey (NHANES III)
13
 and in women aged < 75 years in the 
Carotenoids in Age-Related Eye Disease Study (CAREDS study) but not in those aged 75 and 
over.
16
  Neither study found an association with 25(OH) D and late AMD but the number of 
cases evaluated was small. In the Korean National Health and Nutrition study there was no 
association with early or late AMD overall; separate analyses by gender found reduced odds of 
late AMD with increasing 25(OH)D in men but not in women.
17
  No association of 25(OH)D 
concentrations categorized as deficient (<25 nmol/L) or insufficient (25–49 nmol/L) compared to 
 sufficient (≥50 nmol/L) with either early or late AMD, were observed in a small population 
based study of elderly residents in France.
14
 
In our study, 25(OH)D was measured in stored blood samples collected at the same time as the 
ascertainment of AMD. We cannot therefore exclude the possibility of reverse causation i.e. that 
nvAMD, directly or indirectly, influenced the 25(OH)D levels, for example as a result of 
complement-related or other inflammatory effects.
11
  We had no information on co-morbidities 
which may be either consequences of AMD such as depression and anxiety,
29
 low physical 
activity
30
 or other age-related conditions associated with AMD such as cognitive impairment
31, 32
 
or complement-related conditions such as diabetic nephropathy,
33, 34
 some of which have been 
associated with 25(OH)D.
7, 8
  The conclusion of one substantial review of vitamin D and a wide 
range of health outcomes highlighted a lack of highly convincing evidence for a clear role of 
vitamin D for many health related outcomes in both randomized and observational studies.
8
  
Furthermore, Autier and colleagues suggest that low 25(OH)D is a marker of ill health and that 
inflammatory processes involved in disease manifestation reduce 25(OH)D, explaining why low 
vitamin D status has been reported for a wide range of disorders
7
.  Restoration of vitamin D 
deficits due to ageing and lifestyle changes induced by ill health could explain why low-dose 
supplementation may lead to slight gains in survival in the elderly. 
 Genetic variants in vitamin D pathway members are not subject to concerns of temporality and 
confounding and therefore provide stronger evidence on the possible association of vitamin D 
with AMD.  SNPs in the CYP24A1 and VDR gene were identified in the discovery phase of a 
family nvAMD study but in the replication component, only variants in CYP24A1 were found to 
be associated.
9
  In the CAREDS study, SNPs in CYP2R1 and VDR but not CYP24A1 were 
associated with early AMD.
15
 In our study, we found no significant associations between 
 variants in CYP2R1 and early AMD but a nominal association with two VDR SNPs.  A VDR 
SNP (rs11574077) was significantly associated with nvAMD in our study but this SNP was not 
associated with nvAMD in a family study.
9
 We found the strongest evidence of nominal 
association for SNPs located within the RXRA gene region (rs12339187, rs3118536, rs11185644, 
rs10881582), although these did not withstand correction for multiple testing.  A limitation of 
our study was the small number of cases of early and nvAMD for investigation of genetic 
associations.  
Genetic determinants of vitamin D bioactivity have been identified previously in the genes 
encoding VDR and the retinoic acid-X-receptor (RXRA), which forms a complex with 1,25 OH2 
D bound to VDR and is recognized by vitamin D response elements on target genes.
35
  We 
directly genotyped rs1570669 and rs2274130 in CYP24A1, together with rs927651 as a proxy for 
rs1570670, rs2296239 and rs4809957, all SNPs in high linkage disequilibrium.  We found no 
evidence to support their previously reported association with AMD.
13
  In addition, previous 
reports of VDR SNPs associated with AMD offer little support for our study findings and vice 
versa,
19
 although lack of support may result from discrepancies in recruitment and composition, 
study size and characterization of the AMD cases within each study.  In contrast to a previous 
finding we found no evidence that major AMD genetic risk variants (rs1061170 and rs10490924) 
modified the association between 25(OH)D deficiency and early AMD and nvAMD.
19
  We did 
not find a relationship with RXRA SNPs and 25(OH)D; however, a previous association with one 
RXRA SNP (rs9409929) has been reported only with the metabolite 1,25 OH2 D but not the 
circulating serum level.
36
  It is possible that the nominal association we report between RXRA 
variants and nvAMD may not relate to vitamin D. RXRA receptors are involved in a large 
number of pathways other than those related to vitamin D including, of relevance to AMD, 
 glucose and lipid metabolism
37
 and the omega 3 fatty acid, docosahexaenoic acid.
38
 Previously 
reported genome wide association data evaluated several SNPs across the RXRA gene in 2157 
mixed early and late AMD cases and 1150 controls (http://www.ncbi.nlm.nih.gov/gap) including 
rs10881582, p=0.15, but no evidence of association was found.
39
   
We conclude therefore that the hypothesis of a causal association of vitamin D with AMD is not 
supported by clear evidence for an association of vitamin D pathway SNPs with early, late  or 
nvAMD.  Moreover concerns about residual confounding and reverse causation make it unlikely 
that there is an association between vitamin D deficiency and AMD. 
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 Table 1. Characteristics of participants by vitamin D status 
 
1
 Mean (SD) 
2 
% (n) 
3
 Median, IQR (interquartile range) 
4
 Energy adjusted  
5
 p trend based on log lutein  
 
  
  Serum 25(OH)D status 
nmol/L) 
Sufficient  
>50 (nmol/L) 
Insufficient 
≥30<50 (nmol/L) 
Deficient 
<30 (nmol/L) 
 
N 2077 1475 944 p trend 
Serum 25(OH)D (nmol/L) 
1 
70.2 (16.0) 39.9 (5.7) 21.2 (5.9)  
Age
1
 72.6 (5.4) 73.3 (5.7) 74.5 (6.0) <0.0001 
Women 
2 
47.9 (1055) 53.7 (823) 61.7 (590) 0.11 
Education (lowest tertile of years)
2 
37.4 (769) 36.5 (561) 39.5 (380) 0.42 
Ever smoker 
2 
49.2 (1020) 44.8 (681) 43.3 (414) 0.13 
Alcohol at least weekly
2 
52.2(903) 44.4 (555) 44.0 (374) 0.18 
Annual UVB exposure (MED)
3,5
 237 (123-393) 229 (112-412) 202 (69-380) 0.17 
Obese
2
 (BMI ≥30) 32.1 (645) 40.4 (567) 40.7 (352) 0.05 
Diabetes
2 
12.9 (218) 17.9 (219) 16.7 (147)  0.02 
CVD
2
 12.5 (268) 13.6 (215) 14.3 (142) 0.29 
Fish oil supplement use
2 
8.2 (381) 3.9 (109) 1.5 (22) 0.22 
     
Blood measures
 
 µmol/L
 
    
Cholesterol
1
 5.8 (1.1) 5.6 (1.1) 5.6 (1.0) 0.12 
Vitamin C
1,
 48.4 (24.8) 42.2 (25.4) 40.6 (25.6) 0.02 
Lutein
3,5
 1.26 (0.47-2.79) 0.99 (0.46-2.42) 0.90 (0.46-2.42) 0.05 
Alpha- tocopherol
1
 30.6 (7.0) 30.5 (7.0) 29.9 (6.7) 0.43 
Retinol
1
 2.23 (0.77) 2.19 (0.79) 2.18 (0.74) 0.36 
 
    
Dietary variables     
≥ 1 Oily fish serving per week2 45.8 (892) 36.7 (522) 27.5 (254) 0.02 
Vitamin D
4
 (highest quartile) 30.9 (593) 24.7 (355)   18.2 (153) 0.01 
DHA
4
 (highest quartile) 33.7 (617) 25.9 (350) 17.9 (150) 0.01 
 Table 2.  Association of early, late and neovascular AMD  with (i) 25(OH)D (nmol/L) distribution (ii) Vitamin D status  
 
 
 
 
 
 
 
 
a
 Square root transformed serum 25(OH)D nmol/L 
b
Odds ratio  (OR) and 95% Confidence Interval (95% CI) 
c
Adjusted for age, sex, center, season, smoking, CVD, diabetes, alcohol consumption, BMI, plasma cholesterol, alpha-tocopherol, 
retinol ,lutein, ascorbate. 
d
 Odds ratio (OR) per unit increase of square root transformed serum 25(OH)D 
 
  
 Serum 25(OH)D  
(nmol/L)
a 
 Sufficient  
>50 nmol/L    
Insufficient 
≥30 -<50  nmol/L    
 Deficient 
<30 nmol/L   
 
 
        
 OR (95% CI)
b,c,d 
p Reference OR (95% CI)
b,c
 p OR (95% CI)
b,c
 p 
Early AMD        
  Grade 1 0.98 (0.94-1.01) 0.24 1 0.98 (0.88-1.10) 0.78 0.97 (0.79-1.18) 0.73 
  Grade 2
 1.04 (0.93-1.17) 0.36 1 0.94 (0.71-1.23) 0.65 0.88 (0.54-1.45) 0.62 
  Grade 3 1.03 (0.89-1.20) 0.65 1 0.65 (0.38-1.10) 0.11 1.17 (0.84-1.64) 0.36 
 
       
Late AMD 1.02 (0.94-1,11) 0.59 1 0.76 (0.48-1.20) 0.19 1.21 (0.88-1.68) 0.19 
  Neovascular AMD 1.02 (0.95 -1.08) 0.64 1 0.92 (0.57-1.48) 0.73 1.27 (1.11-1.45) <0.0001 
 Table 7.  Genetic association of SNPs with P<0.05 for (a) serum 25(OH)D (b) early AMD, 
(c) late AMD and (d) neovascular AMD  
(a) Vitamin D CHR SNP Gene      BP BETA (SE)a P 
 
4 rs2298850 GC 72833131 -0.414 (0.116) <0.001 
 
4 rs1155563 GC 72862352 -0.276 (0.116) 0.018 
 
4 rs11939173 GC 72891022 -0.242 (0.106) 0.023 
 
9 rs11185644 RXRA 136350684 -0.277 (0.133) 0.038 
 
11 rs10832306 CYP2R1 14813670 -0.342 (0.169) 0.043 
 
11 rs7935792 CYP2R1 14866037 -0.556 (0.206) 0.007 
 
12 rs2239186 VDR 46555677 -0.390 (0.125) 0.002 
 
12 rs4760169 CYP27B1 56405114 -0.483 (0.167) 0.004 
       
 
CHR SNP Gene BP OR (95% CI)b P 
(b) Early AMD 12 rs11574026 VDR 46574513 0.74 (0.56-0.98) 0.03 
 
12 rs4516035 VDR 46586093 1.21 (1.02-1.44) 0.03 
       (c) Late AMD 9 rs3118536 RXRA 136448283 0.60 (0.41-0.90) 0.01 
 
12 rs10875693 VDR 46555917 1.44 (1.08-1.93) 0.01 
 
12 rs11574077 VDR 46539194 0.32 (0.12-0.84) 0.02 
 
11 rs11023371 CYP2R1 14852847 1.67 (1.01-2.74) 0.04 
       (d) nvAMD 9 rs11185644 RXRA 136350684 0.53 (0.32-0.87) 0.01 
 
9 rs12339187 RXRA 136369148 0.54 (0.33-0.88) 0.01 
 
9 rs10881582 RXRA 136395899 0.64 (0.43-0.97) 0.04 
 
9 rs3118536 RXRA 136448283 0.54 (0.33-0.87) 0.01 
 
12 rs11574077 VDR 46539194 0.18 (0.04-0.76) 0.02 
        
a 
Regression coefficient (Beta) of square root transformed  25(OH)D and Standard error (SE) 
adjusted for age, sex ,center and season. 
b 
Odds Ratio (OR) and 95% Confidence Interval (CI) for early, late and nvAMD adjusted for 
age, sex, center 
Abbreviations: AMD, age related macular degeneration; nvAMD, neovascular age related 
macular degeneration; CHR, chromosome; SNP, single nucleotide polymorphism; BP, base pair;  
 
 
